Genetics

Host: Alan S. Brown, MD, FACC, FAHA, FNLA

Guest: Anne Goldberg, MD

The National Lipid Association Foundation is emphasizing awareness of the most common inherited form of high cholesterol, familial hypercholesterolemia. Endocrinologist Dr. Anne Goldberg, talks with host Dr. Alan Brown about how to recognize and treat this hereditary cause of early onset atherosclerosis. Research has shown that statin treatment should begin when patients are very young. How early in life can we start screening and treating children, and are there differences to consider when treating young male versus female patients?

Brought to you by:

Host: Janet Wright, MD

Guest: Dan Roden, MD

Long QT syndrome can be a silent threat. Although not all patients with congenital long QT syndrome develop symptoms, there is potential for dangerous arrhythmia that can cause sudden cardiac death. Can and should genetic testing guide clinicians in diagnosing and treating this condition? Dr. Dan Roden, professor of medicine and pharmacology and assistant vice-chancellor for personalized medicine at Vanderbilt University School of Medicine, says the concept of personalized medicine goes beyond genetics; it is also about meeting a patient's goals and individual needs. How can genetic testing help physicians decide which medical therapy might be most appropriate for each patient? Dr. Janet Wright hosts.

Host: Matt Birnholz, MD

For people who carry genetic predispositions toward Alzheimer's Disease, little is currently known about predicting the onset, course, and severity of disease at the individual level. However, because cogntitive degenerative diseases most often follow a gradual course of symptom progression later in life, medical professionals must be aware of the distinct, discoverable changes that occur at the "preclinical" stage, i.e prior to the symptomatic onset of memory loss.

In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about Alzheimer's Disease from an unique perspective of the preclinical stage. From classical signs on physicial exam to emerging biomolecular lab tests and novel imaging modalities, the pathophysiologic changes underlying Alzheimer's Disease are explored in depth.

Presenting this session of Grand Rounds is Dr. Richard Caselli, behavioral neurologist and professor of neurology at the Mayo Clnic in Scottsdale, Arizona.

This is Part 3 of a lecture in three parts.

Part 1 >>

Part 2 >>

To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.

Host: Matt Birnholz, MD

For people who carry genetic predispositions toward Alzheimer's Disease, little is currently known about predicting the onset, course, and severity of disease at the individual level. However, because cogntitive degenerative diseases most often follow a gradual course of symptom progression later in life, medical professionals must be aware of the distinct, discoverable changes that occur at the "preclinical" stage, i.e prior to the symptomatic onset of memory loss.

In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about Alzheimer's Disease from an unique perspective of the preclinical stage. From classical signs on physicial exam to emerging biomolecular lab tests and novel imaging modalities, the pathophysiologic changes underlying Alzheimer's Disease are explored in depth.

Presenting this session of Grand Rounds is Dr. Richard Caselli, behavioral neurologist and professor of neurology at the Mayo Clnic in Scottsdale, Arizona.

This is Part 2 of a lecture in three parts.

Part 1 >>

Part 3 >>

To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.

Host: Matt Birnholz, MD

For people who carry genetic predispositions toward Alzheimer's disease, little is currently known about predicting the onset, course, and severity of disease at the individual level. However, because cogntitive degenerative diseases most often follow a gradual course of symptom progression later in life, medical professionals must be aware of the distinct, discoverable changes that occur at the "preclinical" stage, i.e prior to the symptomatic onset of memory loss.

In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about Alzheimer's Disease from a unique perspective of the preclinical stage. From classical signs on physicial exam to emerging biomolecular lab tests and novel imaging modalities, the pathophysiologic changes underlying Alzheimer's disease are explored in depth.

Presenting this session of Grand Rounds is Dr. Richard Caselli, behavioral neurologist and professor of neurology at the Mayo Clnic in Scottsdale, Arizona.

This is Part 1 of a lecture in three parts.

Part 2 >>

Part 3 >>

To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.

Host: Janet Wright, MD

Guest: Christopher O'Donnell, MD, MPH

We know that genes play a role in cardiovascular health, but new research has identified specific DNA regions that are associated with risk factors for coronary heart disease. It's estimated that 30-50% of cardiovascular health is influenced by family history or genetics, while the rest is influenced by other environmental factors, diet and exercise. How might these new genetic discoveries lead to new treatment options? Dr. Christopher O'Donnell, associate director and scientific director of the SHARe Project of the Framingham Heart Study at the National Heart, Lung and Blood Institute, and associate clinical professor of medicine at Harvard Medical School in Massachusetts, talks about his work genotyping the single-nucleotide polymorphisms of large cohort study participants. How are genome-wide association studies leading to discovery of new genes associated with various diseases, and will these findings move us into a new era of prevention and treatment of cardiovascular disease? Dr. Janet Wright hosts.

Host: Mimi Secor, DNP, FNP-BC, FAANP

Guest: Constance Roche

It's estimated that one in eight women will be diagnosed with breast cancer in their lifetime. 75% of women who are diagnosed have no known risk factors. But the incidence and mortality rate of breast cancer has declined over the last couple of decades. The government released controversial amendments to screening recommendations last year based on mortality outcomes from breast cancer. What are the implications for our patients, and what screening guidelines should advanced practice clinicians recommend to patients? Nurse practitioner Constance Roche, a clinical coordinator at the Avon Comprehensive Evaluation Center in Boston, Massachusetts, joins host Mimi Secor to discuss how to identify high risk patients, the best screening techniques and how primary care providers can find the best specialist for their patients.

Host: Bruce Bloom, DDS, JD

Guest: Berish Rubin, PhD

Only a few years ago familial dysautonomia (FD) was a fatal disease, but some "Rediscovery Research" from the FD lab at Fordham University in Bronx, New York, is turning this killer into a chronic manageable disease. What have we learned from familial dysautonomia research, and how might this help patients with other diseases? Joining host Dr. Bruce Bloom to provide an update on current FD research and treatment is Dr. Berish Rubin, professor in the department of biological sciences and head of the laboratory for familial dysautonomia research at Fordham University.

Host: Eric Tangalos, MD

Guest: David Dosa, MD, MPH

Long-term care facilities that include pets as residents are finding that fuzzy friends offer not only companionship to their human residents, but also comfort at the end of life. Dr. David Dosa, geriatrician and health services researcher at Brown University in Providence, Rhode Island, and author of Making Rounds with Oscar: The Extraordinary Gift of an Ordinary Cat, shares his stories about a nursing home cat named Oscar with an uncanny ability to sense when patients are nearing the end of life. What can Oscar teach us about compassionate palliative and hospice care? How prevalent are animal programs at long-term care facilities, and what other benefits do pets offer to residents? How do animal programs fit in with culture change in long-term care? Dr. Eric Tangalos hosts.

Host: Maureen Whelihan, MD

Guest: Michael Krychman, MD

When a woman is first diagnosed with breast cancer, a doctor's first concern is a treatment plan. But what happens after chemotherapy, radiation and surgery? Women must once again learn to reconnect with their bodies. Dr. Michael Krychman, executive director of the Southern California Center for Sexual Health and Survivorship Medicine, joins host Dr. Maureen Whelihan to discuss the treatment of low sexual desire in breast cancer survivors.